title: Severe Chlamydia pneumoniae infection in a patient with mild neutropenia during treatment of Hodgkin's disease.
abstract: Chlamydia pneumoniae is known to cause acute respiratory tract infections in the non-immunocompromised population. So far, no data about the incidence of chlamydial infections in neutropenic patients are available. Macrolide antibiotics are not considered to be first-line treatment options in neutropenic patients. We report the case of a patient with Hodgkin's disease who developed C. pneumoniae pneumonia during mild neutropenia. C. pneumoniae should be considered as a causative agent of pneumonia in neutropenic patients.
authors: III. Medizinische Klinik, Department of Hematology/Oncology, Klinikum Mannheim, University of Heidelberg, Germany. margit.hummel@med3.ma.uni-heidelberg.de
authors: Margit
authors: M
authors: Hummel
authors: Ralf
authors: R
authors: Hofheinz
authors: Dieter
authors: D
authors: Buchheidt
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001372:Aza Compounds / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D023521:Chlamydophila Infections / Q000188:drug therapy / Q000209:etiology* / Q000382:microbiology; D016993:Chlamydophila pneumoniae / Q000302:isolation & purification*; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005260:Female; D024841:Fluoroquinolones; D006689:Hodgkin Disease / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use; D016867:Immunocompromised Host; D000077266:Moxifloxacin; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications*; D018410:Pneumonia, Bacterial / Q000188:drug therapy / Q000209:etiology* / Q000382:microbiology; D011804:Quinolines / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use; D014640:Vancomycin / Q000627:therapeutic use; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D001761:Bleomycin; D014750:Vincristine; D014640:Vancomycin; D015378:Imipenem; D003606:Dacarbazine; D004317:Doxorubicin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D000077266:Moxifloxacin